A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05318573. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT05318573
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2022
- Primary completion
- Apr 30, 2029
- Completion
- Oct 31, 2029
- Last update posted
- Sep 3, 2025
2022 – 2029
United States locations
- U.S. sites
- 23
- U.S. states
- 19
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer and Blood Speciality Clinic | Long Beach | California | 90806 | — |
| Sharp Memorial Hospital (Oncology Clinical Research) | San Diego | California | 92123 | — |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| University of Kansas Cancer Center - Westwood | Westwood | Kansas | 66205 | — |
| University of Kentucky Medical Center | Lexington | Kentucky | 40536 | — |
| University of Louisville Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) | Detroit | Michigan | 48202 | — |
| Washington University School of Medicine, Center for Adv Medicine | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Specialists - Legacy | Omaha | Nebraska | 68130 | — |
| Comprehensive Cancer Centers of Nevada - Southern Hills | Las Vegas | Nevada | 89148 | — |
| Atlantic Health System / Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| TriHealth Cancer Institute; Good Samaritan Hospital | Cincinnati | Ohio | 45220 | — |
| Providence Cancer Institute Franz Clinic | Portland | Oregon | 97213 | — |
| Hospital of the Univ of Pennsylvania Perlman Center | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75235 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Advanced Non Small Cell Lung Cancer trials
Other public records listing Advanced Non Small Cell Lung Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
- NCT06731413: Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) Recruiting
- NCT07222566: Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting
- NCT04613596: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 Recruiting
- NCT06452277: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) Recruiting
- NCT05099172: First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05318573, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2025 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05318573 live on ClinicalTrials.gov.